Search research articles
Contact Us
Filters
Showing results (351-360 of 464) with videos related to
Page
of 47
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2021
Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review
Calen A Steiner, Jeffrey A Berinstein, Jeremy Louissaint, et al.
Alimentary Pharmacology & Therapeutics
|
August 12, 2024
Performance of bowel preparation quality scales in patients with Crohn's disease
Virginia Solitano, Corey A Siegel, Joshua R Korzenik, et al.
The New England Journal of Medicine
|
September 25, 2024
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
Bruce E Sands, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Gastroenterology
|
March 7, 2016
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection
Miguel Regueiro, Brian G Feagan, Bin Zou, et al.
Alimentary Pharmacology & Therapeutics
|
January 11, 2022
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis
Silvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Alimentary Pharmacology & Therapeutics
|
March 4, 2022
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply
Silvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Journal of Crohn'S & Colitis
|
July 8, 2016
Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease
Elena Dubcenco, Guangyong Zou, Larry Stitt, et al.
Contemporary Clinical Trials Communications
|
December 17, 2025
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease
Silvio Danese, Bruce E Sands, Brian G Feagan, et al.
Journal of Crohn'S & Colitis
|
July 26, 2021
Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis
Rocio Sedano, Malcolm Hogan, Tran M Nguyen, et al.
Gut
|
February 18, 2017
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Julian Panés, William J Sandborn, Stefan Schreiber, et al.
Page
of 47
Search research articles
Search
Showing results (351-360 of 464) with videos related to
Sort By:
Page
of 47
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 5, 2021
Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review
Calen A Steiner, Jeffrey A Berinstein, Jeremy Louissaint, et al.
Alimentary Pharmacology & Therapeutics
|
August 12, 2024
Performance of bowel preparation quality scales in patients with Crohn's disease
Virginia Solitano, Corey A Siegel, Joshua R Korzenik, et al.
The New England Journal of Medicine
|
September 25, 2024
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
Bruce E Sands, Brian G Feagan, Laurent Peyrin-Biroulet, et al.
Gastroenterology
|
March 7, 2016
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection
Miguel Regueiro, Brian G Feagan, Bin Zou, et al.
Alimentary Pharmacology & Therapeutics
|
January 11, 2022
Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis
Silvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Alimentary Pharmacology & Therapeutics
|
March 4, 2022
Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply
Silvio Danese, Barrett G Levesque, Brian G Feagan, et al.
Journal of Crohn'S & Colitis
|
July 8, 2016
Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease
Elena Dubcenco, Guangyong Zou, Larry Stitt, et al.
Contemporary Clinical Trials Communications
|
December 17, 2025
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease
Silvio Danese, Bruce E Sands, Brian G Feagan, et al.
Journal of Crohn'S & Colitis
|
July 26, 2021
Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis
Rocio Sedano, Malcolm Hogan, Tran M Nguyen, et al.
Gut
|
February 18, 2017
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Julian Panés, William J Sandborn, Stefan Schreiber, et al.
Page
of 47